University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Public Health Resources

Public Health Resources

2011

HLA-A*3101 and Carbamazepine-Induced Hypersensitivity
Reactions in Europeans
Mark McCormack
Royal College of Surgeons in Ireland

Ana Alfirevic
University of Liverpool, ana.alfirevic@liv.ac.uk

Stephane Bourgeois
Wellcome Trust Sanger Institute

John J. Farrell
Boston University

Dalia Kasperavičiūtė
University College London
See next page for additional authors
Follow this and additional works at: https://digitalcommons.unl.edu/publichealthresources
Part of the Public Health Commons

McCormack, Mark; Alfirevic, Ana; Bourgeois, Stephane; Farrell, John J.; Kasperavičiūtė, Dalia; Carrington,
Mary; Sills, Graeme J.; Marson, Tony; Jia, Xiaoming; de Bakker, Paul I. W.; Chinthapalli, Krishna; Molokhia,
Mariam; Johnson, Michael R.; O'Connor, Gerard D.; Chaila, Elijah; Alhusaini, Saud; Park, B. Kevin; Depondt,
Chantal; Sisodiya, Sanjay M.; Goldstein, David B.; Deloukas, Panos; Delanty, Norman; Cavalleri, Gianpiero
L.; Pirmohamed, Munir; Pichler, Werner; Shianna, Kevin V.; Radtke, Rodney A.; and Pandolfo, Massimo,
"HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans" (2011). Public Health
Resources. 135.
https://digitalcommons.unl.edu/publichealthresources/135

This Article is brought to you for free and open access by the Public Health Resources at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Public Health Resources by
an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.

Authors
Mark McCormack, Ana Alfirevic, Stephane Bourgeois, John J. Farrell, Dalia Kasperavičiūtė, Mary
Carrington, Graeme J. Sills, Tony Marson, Xiaoming Jia, Paul I. W. de Bakker, Krishna Chinthapalli, Mariam
Molokhia, Michael R. Johnson, Gerard D. O'Connor, Elijah Chaila, Saud Alhusaini, B. Kevin Park, Chantal
Depondt, Sanjay M. Sisodiya, David B. Goldstein, Panos Deloukas, Norman Delanty, Gianpiero L. Cavalleri,
Munir Pirmohamed, Werner Pichler, Kevin V. Shianna, Rodney A. Radtke, and Massimo Pandolfo

This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
publichealthresources/135

The

n e w e ng l a n d j o u r na l

of

m e dic i n e

original article

HLA-A*3101 and Carbamazepine-Induced
Hypersensitivity Reactions in Europeans
Mark McCormack, B.A., Ana Alfirevic, M.D., Ph.D., Stephane Bourgeois, Ph.D.,
John J. Farrell, M.S., Dalia Kasperavičiūtė, Ph.D., Mary Carrington, Ph.D.,
Graeme J. Sills, Ph.D., Tony Marson, M.B., Ch.B,, M.D., Xiaoming Jia, M.Eng.,
Paul I.W. de Bakker, Ph.D., Krishna Chinthapalli M.B., B.S.,
Mariam Molokhia, M.B., Ch.B., Ph.D., Michael R. Johnson, D.Phil.,
Gerard D. O’Connor, M.R.C.P.I., Elijah Chaila, M.R.C.P.I.,
Saud Alhusaini, M.B., Kevin V. Shianna, Ph.D., Rodney A. Radtke, M.D.,
Erin L. Heinzen, Ph.D., Nicole Walley, B.S., Massimo Pandolfo, M.D., Ph.D.,
Werner Pichler, M.D., B. Kevin Park, Ph.D., Chantal Depondt, M.D., Ph.D.,
Sanjay M. Sisodiya, M.D., Ph.D., David B. Goldstein, Ph.D.,
Panos Deloukas, Ph.D., Norman Delanty, B.M., Gianpiero L. Cavalleri, Ph.D.,
and Munir Pirmohamed, Ph.D., F.R.C.P.

A bs t r ac t
Background
The authors’ affiliations are listed in the
Appendix. Address reprint requests to
Dr. Alfirevic at the Wolfson Centre for
Personalised Medicine, Department of
Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Block A: Waterhouse
Bldgs., 1-5 Brownlow St., Liverpool L69
3GL, United Kingdom, or at ana.alfirevic@
liv.ac.uk.
Mr. McCormack, Dr. Alfirevic, Dr. Cavalleri,
and Dr. Pirmohamed contributed equally
to this article.
N Engl J Med 2011;364:1134-43.
Copyright © 2011 Massachusetts Medical Society.

Carbamazepine causes various forms of hypersensitivity reactions, ranging from
maculopapular exanthema to severe blistering reactions. The HLA-B*1502 allele has
been shown to be strongly correlated with carbamazepine-induced Stevens–Johnson
syndrome and toxic epidermal necrolysis (SJS–TEN) in the Han Chinese and other
Asian populations but not in European populations.
Methods

We performed a genomewide association study of samples obtained from 22 subjects
with carbamazepine-induced hypersensitivity syndrome, 43 subjects with carbamaze
pine-induced maculopapular exanthema, and 3987 control subjects, all of European
descent. We tested for an association between disease and HLA alleles through
proxy single-nucleotide polymorphisms and imputation, confirming associations
by high-resolution sequence-based HLA typing. We replicated the associations in
samples from 145 subjects with carbamazepine-induced hypersensitivity reactions.
Results

The HLA-A*3101 allele, which has a prevalence of 2 to 5% in Northern European
populations, was significantly associated with the hypersensitivity syndrome
(P = 3.5×10−8). An independent genomewide association study of samples from subjects with maculopapular exanthema also showed an association with the HLAA*3101 allele (P = 1.1×10−6). Follow-up genotyping confirmed the variant as a risk
factor for the hypersensitivity syndrome (odds ratio, 12.41; 95% confidence interval
[CI], 1.27 to 121.03), maculopapular exanthema (odds ratio, 8.33; 95% CI, 3.59 to
19.36), and SJS–TEN (odds ratio, 25.93; 95% CI, 4.93 to 116.18).
Conclusions

The presence of the HLA-A*3101 allele was associated with carbamazepine-induced
hypersensitivity reactions among subjects of Northern European ancestry. The presence
of the allele increased the risk from 5.0% to 26.0%, whereas its absence reduced the
risk from 5.0% to 3.8%. (Funded by the U.K. Department of Health and others.)
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C

arbamazepine is one of the most
commonly prescribed drugs for the treatment of epilepsy, as well as trigeminal neuralgia and bipolar disorder. A minority of treated
persons have hypersensitivity reactions that vary
in prevalence and severity,1 with some forms associated with substantial morbidity and mortality. The mildest form, maculopapular exanthema,
occurs in 5 to 10% of treated persons of European ancestry and resolves spontaneously after
drug discontinuation. More severe reactions, such
as the hypersensitivity syndrome, are associated
with mortality of up to 10%2 and include symptoms such as rash, fever, eosinophilia, hepatitis,
and nephritis. The most severe reactions, such as
the Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), are characterized by a
blistering rash affecting a variable percentage of
the body-surface area. The rate of death increases
with the degree of epidermal detachment. TEN is
the rarest of these phenotypes and is associated
with mortality of up to 30%. According to the
labeling of carbamazepine, as mandated by the
Food and Drug Administration (FDA), the estimat
ed incidence of SJS–TEN is 1 to 6 cases in 10,000
persons of European ancestry who are exposed
to the drug.
Genomewide approaches are increasingly used
to identify genetic predisposing factors for druginduced hypersensitivity reactions and druginduced liver injury.3 For example, the HLAB*1502 allele has been identified as a clinically
important predictor of SJS–TEN in Asians of Han
Chinese descent who are candidates for treatment with carbamazepine.4 This finding led the
FDA to require a warning label for carbamazepine
to indicate the need for genotyping for HLAB*1502 before the drug is prescribed. This change
seems warranted, given the prospective study
described in this issue of the Journal,5 which
shows that withholding carbamazepine from
subjects of Han Chinese ancestry who carry the
HLA-B*1502 allele substantially decreased the
rate of the development of SJS–TEN. The value of
HLA-B*1502 in predicting the risk of SJS–TEN
has been shown in other Asian populations, including those of Thailand, Malaysia, and India.4,6-8
This effect is specific for SJS–TEN, as compared
with the full spectrum of carbamazepine-related
hypersensitivity reactions, which led to the suggestion that different phenotypes of carbamaze-
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pine-induced hypersensitivity may have distinct
genetic predictors. Furthermore, HLA-B*1502 is
rare (with a prevalence of less than 2%) in populations of European descent, in which carbamaz
epine-induced SJS–TEN occurs at a lower incidence than in Asian populations.9-12 Using a
candidate-gene approach, previous studies have
shown weak or moderate signals of association
between maculopapular exanthema or the DRESS
(drug reaction with eosinophilia and systemic
symptoms) syndrome and single-nucleotide poly
morphisms (SNPs) in the major histocompatibility complex (MHC) region,13-15 and these associations have not been consistently replicated.13,14
We present data from two independent studies
that suggest the relevance of an HLA variant to
the clinical spectrum of carbamazepine-related
hypersensitivity reactions, including maculopapular exanthema, the hypersensitivity syndrome,
and SJS–TEN.

Me thods
Case Subjects

Recruitment

We recruited case subjects at centers collaborating with the University of Liverpool and Walton
Centre for Neurology (both hereinafter referred
to as “the Liverpool collaborators”) or at centers
affiliated with the EPIGEN consortium (for details, see the Supplementary Appendix, available
with the full text of this article at NEJM.org). All
case subjects and control subjects were of European ancestry as determined by either self-report
or genetic-marker analysis.13 Many of these subjects have been described previously in the context of hypersensitivity reactions.9,13,16
Hypersensitivity Syndrome

The group with the hypersensitivity syndrome
consisted of 26 subjects: 23 who were recruited
through the Liverpool collaborators and 3 who
were recruited through the EPIGEN consortium.
The hypersensitivity syndrome was defined as
the presence of rash or liver involvement within
3 months after the initiation of carbamazepine
treatment, accompanied by a minimum of two of
the following manifestations: a prolonged recovery phase, despite withdrawal of the drug; fever;
involvement of other internal organs (liver, kidney,
lung, central nervous system, heart, muscle, thy-
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roid, or lymphoid system); or the presence of hematologic abnormalities, such as eosinophilia
and atypical lymphocytosis.17 We considered the
DRESS syndrome to be the same as the hypersensitivity syndrome.
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Clinical Controls

The clinical control group consisted of 257 subjects with epilepsy who had been taking carba
mazepine for at least 3 months with no clinical
or biochemical signs of hypersensitivity. Of these
subjects, 44 were recruited by the Liverpool collaborators and 213 were recruited from clinics
Acute Generalized Exanthematous Pustulosis
We recruited one subject with acute generalized affiliated with EPIGEN.
exanthematous pustulosis (AGEP), who had a
typical pustular reaction with high fever,18 from Genomewide Genotyping
a collaborating clinic in Switzerland. We then Genomewide analysis of samples that were inianalyzed the data from this subject together with tially available from the 22 Liverpool subjects
data from the subjects with the hypersensitivity with carbamazepine-induced hypersensitivity syndrome was performed with the use of the Illusyndrome.
mina Infinium 1.2M chip at the Wellcome Trust
Sanger Institute. Samples from 43 case subjects
Maculopapular Exanthema
The group with maculopapular exanthema con- and 200 control subjects from the EPIGEN consisted of 106 subjects: 57 who were recruited sortium were genotyped with the use of the Illuthrough the Liverpool collaborators and 49 who mina 610K Quad platform at the Duke University
were recruited through the EPIGEN consortium. Center for Human Genome Variation. (Details
Maculopapular exanthema was defined as rash regarding quality controls and principal-compowithout systemic symptoms that required the dis- nents analysis are provided in the Supplementary
continuation of carbamazepine within 3 months Appendix.)
after the initiation of drug therapy.
Imputation of HLA Alleles

SJS–TEN

The SJS–TEN group consisted of 12 subjects: 8 who
were recruited through the Liverpool collaborators
and 4 who were recruited through the EPIGEN
consortium. The diagnostic criteria suggested by
the RegiSCAR Project (a research network for severe cutaneous adverse drug reactions)11,19 were
used for this group (see the Supplementary Appendix).
Control Subjects

Population Controls

Genotype data from the Wellcome Trust Case
Control Consortium (WTCCC) (www.wtccc.org
.uk) were used as a population control group. The
Liverpool collaborators used data from a genomewide association study of samples from 2691
subjects in the U.K. National Blood Services Collection. EPIGEN used samples from a homogeneous subgroup of 1296 subjects in the 1958 British Birth Cohort that were selected by principal
component analysis. We did not screen either set
of population controls for carbamazepine-related
adverse drug reactions. (For details about our
access to these data, see the Supplementary Appendix.)

1136
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We based the imputation of classic HLA alleles in
samples from the 22 Liverpool subjects with the
hypersensitivity syndrome and control subjects
from the U.K. National Blood Service on a dense
reference panel of SNP data and four-digit HLA
types in 2767 unrelated subjects of European descent, according to a method described recently.20
We imputed classic HLA alleles in the samples
from the EPIGEN consortium, using MACH 1.0 on
the Web site of the Center for Statistical Genetics
(www.sph.umich.edu/csg/abecasis/MACH).21 The
1458 subjects in the HLA-typed 1958 British Birth
Cohort constituted the reference population. (See
the Supplementary Appendix for further details.)
We used different approaches to impute the HLA
alleles in the Liverpool and EPIGEN subjects,
because the two studies were originally independent.
HLA-A High-Resolution Genotyping

To confirm the accuracy of imputation, highresolution, sequence-based HLA-A typing of samples from 22 subjects with the hypersensitivity
syndrome and from a subgroup of 44 clinical
control subjects (i.e., subjects who did not have
adverse reactions to carbamazepine) was per-
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formed by Histogenetics. We determined the
HLA-A alleles in samples from 49 subjects with
maculopapular exanthema and a subgroup of 213
clinical control subjects from the EPIGEN consortium, using sequence-specific polymerase-chainreaction assay primers (details available on request).
Direct genotyping showed 100% concordance
with the imputed alleles.
HLA-A* 3101 Proxy SNP Genotyping

Genotyping of the rs1061235 SNP in samples
from all Liverpool subjects (including case subjects with maculopapular exanthema, the hypersensitivity syndrome, or SJS–TEN and clinical
control subjects) was performed by KBioscience.
This allele has previously been shown to be in
complete linkage disequilibrium (r2 = 1) with the
HLA-A*3101 allele in populations of European
descent.22
Statistical Analysis

Statistical analyses were performed with the use
of PLINK (version 1.05),23 RevMan (version 5)
(http://ims.cochrane.org/revman), and Haploview24
software packages. For the genomewide association studies, both the Liverpool collaborators and
the EPIGEN consortium used logistic regression
with an additive model of inheritance. They adjusted for population stratification by including
significant principal components as covariates in
the logistic-regression model and used a P value
of less than 5.0×10−8 to indicate genomewide significance. Pooled analysis of the different groups
of subjects was performed to estimate odds ratios
and confidence intervals from summary data with
the use of a random-effects model. Between-study
heterogeneity was tested by calculating I2 and
Tau.2 The z-score directionality or estimated risk
was checked for consistency with observed data.

R e sult s
Association with the Hypersensitivity
Syndrome

We first conducted an association analysis involving 1.2M SNPs in samples from the 22 Liverpool subjects with carbamazepine-induced hypersensitivity syndrome and from 2691 healthy
controls from the U.K. National Blood Services
Collection. (The full set of results can be obtained
from the European Genotype Archive, access num-
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ber EGAS00000000037.) We identified a strong
signal in the MHC region on chromosome 6, with
several SNPs around HLA-A reaching genomewide significance (P = 3.5×10−8) (Fig. 1A and 1B).
This variant was seen in 40.0% of case subjects
but in only 4.9% of control subjects. The top hit
(rs1061235) had previously been shown to be a
proxy for the HLA-A*3101 allele in persons of
European descent.22 Therefore, we focused on
this locus as a predictor of response through
high-resolution, sequence-based HLA-A typing,
which confirmed the absolute correlation (r2 = 1)
between rs1061235 and HLA-A*3101 that had
been observed previously.22 No other classic HLA-A
alleles reached nominal significance (Table 1 in
the Supplementary Appendix).
During the course of this study, samples from
4 additional subjects with the hypersensitivity
syndrome and from 1 additional subject with
AGEP became available from the Liverpool and
EPIGEN centers. Of these 5 subjects, 2 (including
the single subject with AGEP) tested positive for
HLA-A*3101. A comparison of all 27 subjects with
the 257 control subjects without adverse drug
reactions produced an odds ratio of 12.41 (95%
confidence interval [CI], 1.27 to 121.03; P = 0.03)
(Fig. 2).
Association with Maculopapular Exanthema

EPIGEN investigators performed a genomewide
association study of samples from 43 subjects
with maculopapular exanthema and 1296 healthy
control subjects from the 1958 British Birth Cohort. (The full set of results can be obtained from
dbGAP, access number EGAS00000000036.) HLAA*3101 was the most strongly associated allele
(P = 1.11×10−6) and was observed in 27% of case
subjects and 4% of control subjects, although the
effect was not significant genomewide (Fig. 3 in
the Supplementary Appendix). However, we had access to another 63 case subjects with maculopap
ular exanthema and 257 control subjects without
adverse drug reactions. Our combined analysis of
all 106 subjects with maculopapular exanthema
and the 257 clinical control subjects showed a
significant allelic association with HLA-A*3101
(P = 8.0×10−7), generating an odds ratio of 8.33
(95% CI, 3.59 to 19.36) (Fig. 2). Although the
analyses of samples from subjects with maculopapular exanthema and those with the hypersensitivity syndrome were carried out in the Nether-
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Figure 1. Results of a Genomewide Association Study of Samples from Case Subjects with Carbamazepine-Induced
Hypersensitivity Syndrome and Control Subjects.
Panel A shows a Manhattan plot for logistic regression with a strong signal in the HLA-A region on chromosome 6.
Each dot represents a P value for the comparison of 22 case subjects with the hypersensitivity syndrome and 2691
healthy control subjects from the Wellcome Trust Case Control Consortium. Panel B shows P values for single-nucleotide polymorphisms (SNPs) in the HLA-A region. There is a strong association between carbamazepine-induced
hypersensitivity syndrome and the HLA-A*3101 allele, with identification of the allele in 40.0% of case subjects and
only 4.9% of control subjects. The x axis shows the SNP position on chromosome 6 (National Center for Biotechnology Information build 36). The left y axis shows the negative log10 of P values for the comparison between case subjects and control subjects, as calculated with logistic regression. The right y axis shows the recombination rate on
chromosome 6 between 29 and 31 Mb. The diamonds show the degree of linkage disequilibrium (LD) in the samples.
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lands and Liverpool, respectively, the effect size to immune-mediated adverse reactions, such as
of HLA-A*3101 on risk was consistent across the drug-induced hypersensitivity4,25-27 and liver inEPIGEN and U.K. groups.
jury.3,28 The most prominent example thus far is
the strong predictive value of the HLA-B*5701
Association with SJS–TEN
allele for hypersensitivity to the drug abacavir,
On the basis of our hypothesis that the HLA- used for the treatment of human immunodefiA*3101 allele is associated with carbamazepine- ciency virus infection.25,26,29 FDA guidelines now
induced SJS–TEN, we genotyped HLA-A*3101 in recommend HLA-B*5701 testing in advance of
a group of 12 subjects with SJS–TEN who were abacavir prescription. Testing results in a reducrecruited from both the Liverpool and EPIGEN- tion in the incidence of abacavir hypersensitiviaffiliated centers. Of these 12 subjects, 5 (42%) ty27,30 and is cost-effective.29,31
carried the allele, as compared with 10 (4%) of the
Our study now provides strong evidence sug257 clinical control subjects (odds ratio, 25.93; gesting that HLA-A*3101 is a predictor of carba95% CI, 4.93 to 116.18; P = 8.0×10−5) (Fig. 2).
mazepine hypersensitivity in Europeans. First,
A pooled analysis of all 145 subjects with despite the small number of subjects who were
carbamazepine-induced hypersensitivity and 257 included in the analysis, this signal had genomecontrol subjects without adverse drug reactions wide significance. Second, the signal was obshowed a strong association between hypersen- served across independent groups of case subjects
sitivity and the HLA-A*3101 allele (odds ratio, with different phenotypes of carbamazepine hy9.12; 95% CI, 4.03 to 20.65; P = 1.0×10−7). On the persensitivity, with the use of independent sets
basis of this pooled collection, we calculated of control subjects. Third, HLA-A*3101 has prethat the presence of HLA-A*3101 had a sensitiv- viously been shown to be associated with multiple
ity of 26% and a specificity of 96% as a predic- carbamazepine-hypersensitivity phenotypes, intor of carbamazepine-associated hypersensitivity. cluding SJS–TEN in Japanese subjects15,32 and
Given that carbamazepine hypersensitivity has a with carbamazepine-induced maculopapular exprevalence of 5% (1:20), application of the test anthema in subjects of Han Chinese ancestry.14
criteria from our pooled analysis would increase The one subject in our study who had AGEP, a
the post-test probability to 26% (approximately reaction characterized by sterile pustules, neutro1:4) on the basis of the positive likelihood ratio philic inflammation, and high levels of interleuof 6.74 (95% CI, 3.51 to 13.00). Since the nega- kin-8 in skin,33 also was found to carry the
tive likelihood ratio was 0.77 (95% CI, 0.67 to HLA-A*3101 allele. The prevalence of this allele is
0.84), a negative HLA-A*3101 test would reduce 2 to 5% in Northern European populations, 2%
the probability of hypersensitivity from 5.0% to in Han Chinese populations, and 9% in Japanese
3.8% (1:26 ratio).
populations.32,34,35 The finding that HLA-A*3101
is associated with carbamazepine-induced hypersensitivity in populations of different ancestries
Discussion
parallels the finding of HLA-B*5701-associated
We found that a variation in the presence of the abacavir hypersensitivity.30,36
HLA-A*3101 allele is an important predictor of
HLA-B*1502, a predictor of carbamazepine
the full spectrum of carbamazepine-induced hy- hypersensitivity reactions in Asian populations,
persensitivity reactions in persons of European seems to be phenotype-specific in that it predescent. Such reactions range from the relatively dicts the development of SJS–TEN but not the
mild but nevertheless troublesome maculopapu- development of the hypersensitivity syndrome or
lar exanthema to more severe reactions, such as maculopapular exanthema.14 This finding has led
the hypersensitivity syndrome and SJS–TEN. Al- to the suggestion that the pathogenesis of carbathough the presence of the HLA-A*3101 allele is mazepine-induced SJS–TEN is distinct from that
neither necessary nor sufficient for the develop- of the hypersensitivity syndrome. This hypothement of hypersensitivity to carbamazepine, it is sis is based on the fact that class I alleles are
associated with a significantly increased risk.
usually associated with specific CD8+ cytotoxic
Our data add to growing evidence of the role T-cell reactions, which is consistent with the
of different HLA alleles in predisposing patients known pathologic features of SJS–TEN.37 How-
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Carbamazepine
Reaction
No. Positive
for the
HLA-A*3101
Allele

Total
No.

n e w e ng l a n d j o u r na l

Controls
No. Positive
for the
HLA-A*3101
Allele

Hypersensitivity syndrome
0
EPIGEN
3
9
10
UK
24
1
10
Subtotal
27
10
Heterogeneity: tau2=1.03, chi2=1.58; 1 df, P=0.21; I2=37%.
Test for overall effect: z=2.17; P=0.03
Maculopapular exanthema
EPIGEN
13
49
9
UK
10
57
1
Subtotal
23
106
10
Heterogeneity: tau2=0.00, chi2=0.01; 1 df, P=0.92; I2=0%.
Test for overall effect: z=4.93; P=8.0×10−7
Stevens–Johnson syndrome
EPIGEN
2
4
9
UK
3
8
1
Subtotal
5
12
10
Heterogeneity: tau2=0.00, chi2=0.01; 1 df, P=0.93; I2=0%.
Test for overall effect: z=3.94; P=8.0×10−5
All phenotypes
15
9
EPIGEN
56
23
1
UK
89
38
10
Subtotal
145
Heterogeneity: tau2=0.00, chi2=0.35; 1 df, P=0.55; I2=0%.
Test for overall effect: z=5.30; P=1.0×10−7
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Study Weighting (%)

Odds Ratio (95% CI)

Total
No.
213
44
257

39.4
60.6
100

3.08 (0.15–63.89)
30.71 (3.61–261.65)
12.41 (1.27–121.03)

213
44
257

83.8
16.2
100

8.19 (3.26–20.56)
9.15 (1.12–74.47)
8.33 (3.59–19.36)

213
44
257

58.2
41.8
100

22.67 (2.86–179.73)
25.80 (2.24–297.58)
25.93 (4.93–116.18)

213
44
257

83.9
16.1
100

8.29 (3.40–20.23)
14.98 (1.95–115.09)
9.12 (4.03–20.65)

0.002

0.1

1.0

HLA-A*3101
Less Likely

10.0

500.0

HLA-A*3101
More Likely

Figure 2. Distribution of the HLA-A*3101 Allele across the Spectrum of Clinical Phenotypes of Case Subjects with Carbamazepine-
Induced Hypersensitivity and Control Subjects without Adverse Reactions to Carbamazepine.
Subjects were recruited at centers collaborating with the University of Liverpool and Walton Centre for Neurology (UK) or centers affiliated with the EPIGEN consortium. The sample obtained from one patient with acute generalized exanthematous pustulosis (AGEP) was
analyzed with the samples for the group of case subjects with the hypersensitivity syndrome. Since there were no observations of the
HLA-A*3101 allele in the three case subjects with the hypersensitivity syndrome in the EPIGEN cohort, 0.5 was added to each value in a
two-by-two contingency table to estimate an odds ratio. One patient with the Stevens–Johnson syndrome and toxic epidermal necrolysis
(SJS–TEN) was of mixed European and Thai ancestry. Study weighting (indicated by different sizes of squares) refers to the proportion
of subjects who were recruited from each study cohort. Diamonds indicate pooled odds ratios. The horizontal lines indicate 95% confidence intervals. The abbreviation df denotes degrees of freedom, and I2 is the percentage of total variation that is due to heterogeneity
rather than chance.

ever, our data suggest that the class I allele HLAA*3101 may be important for an increased range
of phenotypes, including maculopapular exanthema and the hypersensitivity syndrome, at least
in European populations. Persons with carba
mazepine-induced hypersensitivity syndrome have
been shown to have several types of drug-specific T cells in peripheral blood, including CD4+,
CD8+, and CD4-CD8+ cells.38 Although there is
1140
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no obvious relationship between HLA-A*3101
and HLA-B*1502, reports have indicated a possible overlap in peptide-binding specificity.39 Given the degree of linkage disequilibrium across
the extended MHC region, we cannot be certain
that either HLA-B*1502 or HLA-A*3101 is causal.
We used samples from healthy volunteers in
the WTCCC as control subjects for both genomewide association studies. Given that the
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hypersensitivity syndrome occurs in 1 in 5000 to
1 in 10,000 persons, it is unlikely that more than
one or two population control subjects would be
at risk for hypersensitivity with exposure to carbamazepine. The larger WTCCC collections therefore afforded increased power over that provided
by comparison of case subjects with the clinical
control subjects. Nevertheless, in analyses involving the 257 clinical control subjects, the association with HLA-A*3101 remained strong for both
the hypersensitivity syndrome (odds ratio, 12.41;
95% CI, 1.27 to 121.03) and SJS (odds ratio,
25.93; 95% CI, 4.93 to 116.18), although the effect size was smaller with maculopapular exanthema (odds ratio, 8.33; 95% CI, 3.59 to 19.36).
Additional studies in populations of European descent and other ancestry are required to
further characterize this association. The International Serious Adverse Event Consortium is
coordinating a global effort to recruit subjects
with drug-induced severe adverse events (www
.saeconsortium.org). Efforts such as this will facilitate the analysis of larger groups of subjects,
which may well uncover other genetic variants
associated with a smaller effect size or population-specific variants. Additional work is also
required to determine whether the effect of the
HLA-A*3101 allele is specific to carbamazepine
or whether it also applies to other drugs. A prospective study that is based on the results we
present here would facilitate the routine clinical
use of HLA-A*3101 testing in carbamazepine
treatment. In this issue of the Journal, a report
describes how prospective HLA-B*1502 typing
can prevent carbamazepine-induced SJS–TEN in
Han Chinese populations.5
We propose that HLA-A*3101 is clinically relevant as a marker to predict hypersensitivity reactions. On the assumption that the prevalence of
carbamazepine-induced hypersensitivity is 5.0%,
the presence of the HLA-A*3101 allele increases
the risk of hypersensitivity to 26.0%, whereas its
absence reduces the risk to 3.8%. Among Japanese patients, the estimated reduction is from
2.9% to 1.1%. The sensitivity and specificity
values estimated here for Europeans (26% and
96%) and by others for Japanese populations
(61% and 88%)32 vary. Among a number of possible reasons for these differences are differences
in study size, in the frequency of HLA-A*3101
(and potential interacting variation), and in the
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effect size of the allele across the two populations.
Nonetheless, these numbers are similar to those
underlying the test criteria calculated for the
presence of the HLA-B*5701 allele and abacavir
hypersensitivity (sensitivity, 45.5%; specificity,
97.6%; and a risk reduction from 7.8% to 2.7%).
On the basis of our data, we have calculated
that 83 patients would need to be screened to
prevent one case of carbamazepine hypersensitivity; the number in the Japanese population is
56. However, it is important to note that this
calculation is based on a conservative estimate
of the prevalence of carbamazepine hypersensitivity (5%). The prevalence of carbamazepine-induced hypersensitivity that was determined in the
context of the Standard and New Antiepileptic
Drugs (SANAD) trial (Current Controlled Trials
number, ISRCTN38354748) (also involving subjects
of European descent) was 10%.40 On the basis of
this prevalence, the number of persons who
would need to be screened to prevent one instance of carbamazepine-induced hypersensitivity is 39. We therefore suggest that consideration
be given to adding the association with HLAA*3101 to the drug label for carbamazepine.
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Methods
Recruiting centres
University of Liverpool collaborators included the UK national prospective SANAD study, the
EUDRAGENE study and Universitätsspital Bern (Switzerland). The EPIGEN Consortium includes Duke
University (North Carolina), University College London (UK), Université Libre de Bruxelles (Brussels,
Belgium) and the Royal College of Surgeons and Beaumont Hospital in Dublin, Ireland.
Definition of Stevens Johnson Syndrome
SJS was defined as skin detachment 1-10% (SJS), 10-30% (overlap syndrome) and >30% (TEN), the
presence of atypical target lesions predominately on the trunk and face, severe, often haemorrhagic,
erosions of mucous membranes. Other manifestations indicating systemic involvement included fever,
liver chemistry elevations, intestinal and pulmonary manifestations, presence of lymphopenia).
Data access for healthy controls
Individual-level genotype data (Illumina 1.2M (custom chip) were accessed for both sets of healthy
controls by application to the Wellcome Trust Case Control Consortium Data Access Committee
(https://www.wtccc.org.uk/ccc1/access_to_data_samples.shtml).

Details on cleaning of Illumina data
Illumina 1.2M on 22 HSS cases: The Illumina gender markers were utilized to compare clinical data with
the DNA sample gender. Hardy-Weinberg equilibrium was estimated and SNPs which failed (p< 0.0001)
in control population were excluded from further analyses. In addition, SNPs with MAF <1% and SNPs
with genotype success rate < 97% were excluded. Final Manhattan plot cleansing step was based on low
intensities and regional LD estimates. Accurate annotation of the variant names and strand orientation
by explicit specification of the version of the human genome assembly and of dbSNP ensured
compatibility of different datasets for comparison in pooled analysis of case-control studies.
Illumina 610k on 49 EPIGEN MPE cases: All quality control measures were performed using PLINK. All
SNPs with a genotyping success rate < 90%, those with MAF < 2% and subjects with genotyping success
rate < 95% were excluded from the dataset. SNPs that were outside a Hardy-Weinberg Equilibrium
threshold of p<0.0001 in control subjects were also removed. To correct for potential cryptic
relatedness, the dataset was thinned to SNPs in linkage equilibrium (SNPs with r2<0.25) and identity-bydescent of overall genome was calculated with a cut-off threshold of 12% shared with another
individual. Population structure was determined by principal components analysis and outliers were
removed.

Details of imputation of HLA alleles in EPIGEN Consortium samples:
We imputed HLA types across 5 loci (HLA-A, B, C, DR, DQ) to the level of 4 digits maximum. To achieve
this, our full GWAS dataset was reduced to SNPs within the HLA locus (NCBI Build 36, base positions
25760204 to 33529555 on chromosome 6). All MPE cases and CBZ-tolerant controls were imputed
together as one population. . Background European HLA allele frequencies were obtained from
www.allelefrequencies.net 21 and through the Irish Blood Transfusion Service Bone Marrow Registry 22.
The quality of the imputation by MACH is described by an r2 value for each HLA type imputed. The
quality threshold was set to r2>0.9. Summary information and quality scores per HLA type imputed are
available upon request.
Background European HLA allele frequencies were obtained from www.allelefrequencies.net21 and
through the Irish Blood Transfusion Service Bone Marrow Registry22
HLA-A *3101 SSP genotyping:
In order to validate the association with the imputed HLA-A*3101 (in EPIGEN samples), we performed
an established wet lab technique to confirm the presence of HLA alleles by amplification of genomic
DNA with sequence specific primers (SSP) in a polymerase chain reaction. Sequence-specific primers for
HLA-A*3101 were obtained with kind permission from Mary N. Carrington of the National Cancer
Institute- Frederick (Maryland, USA) for detecting HLA-A*3101 across the entire EPIGEN cohort. The
forward primer sequence is 5’-GATAGAGCAGGAGAGGCCT-3’ and the reverse primer sequence is 5’AGCGCAGGTCCTCGTTCAA-3’. Visualisation of confirmatory bands was possible by placing an electric
current across a 2% agarose gel containing the samples (see Figure 4 below).
All samples were correctly imputed as each HLA-A*3101 allele carrier was positively identified by the
SSP typing method.
Details of population stratification
Principle component analysis was performed to assess genetic markers for ethnicity. All participants
were self reported Caucasans. Only individuals with genetically matching Caucasian ethnicity were
included into the association analysis. We were working with Phase 1 1958 controls (n=1500), we
removed 204 outliers from PCA plot leaving us with 1296 samples for case/control analysis. PCA plots
for Liverpool HSS (n=22) in conjunction with healthy controls (n=2291) and EPIGEN MPE and EPIGEN
controls are shown in Supp Fig 1 and Supp Fig 2 below respectively.

Results
Table 1. High resolution sequence-based HLA-A typing in patients with carbamazepine (CBZ)-induced
hypersensitivity syndrome and CBZ-tolerant patients.
HLA
allele‡

Allelic
Hypersensitive Allelic
P-value
Frequency patients
Frequency

Odds Ratio
(95% CI)

A*0101g§

CBZtolerant
controls
17

0.19

12

0.27

0.3729

1.57 (0.6703-3.6595)

A*0201g

21

0.24

8

0.18

0.511

0.71 (0.2855-1.7605)

A*0301g

11

0.13

0

0

0.0601

0.08 (0.0044-1.3157)

A*1101g

11

0.13

3

0.07

0.3839

0.51 (0.1352-1.9399)

A*2301g

2

0.02

0

0

1

0.39 (0.0183-8.2745)

A*2402g

3

0.03

5

0.11

0.1162

3.63 (0.8263-15.969)

0

0

1

0.02

0.2576

A*2501g

5

0.06

1

0.02

0.6631

6.10
(0.2436152.9367)
0.39 (0.0437-3.4093)

A*2601g

6

0.07

2

0.05

0.7182

0.65 (0.1259-3.365)

A*2608

1

0.01

0

0

1

0.66 (0.0262-16.419)

A*3001g

3

0.03

0

0

0.6622

0.27 (0.0139-5.4331)

A*3002

1

0.01

0

0

1

0.66 (0.0262-16.419)

1

0.01

8

0.18

3

0.03

1

0.02

0.00064 19.33
(2.3325160.2439)
1
0.66 (0.0665-6.5245)

0

0

2

0.05

0.1078

0

0

1

0.02

0.2576

3

0.03

0

0

0.6645

A*2403g

A*3101g
A*3201
A*3303g
A*6801
A*6801g
Total
alleles

88

10.41
(0.489221.697)
6.10
(0.2436152.9367)
0.27 (0.0139-5.4331)

44

‡

Antigen recognition site allele

§

Alleles bearing suffix 'g' in A locus have identical sequences in exon 2 and exon 3 antigen recognition
sites.

An association between HSS and HLA-A*3101 presence was identified (OR 24.6; 95% CI 2.8, 214.0);
P=0.00004). No other HLA-A alleles showed statistically different allelic frequencies.

Figure 1. Population stratification detection using GWAS in WTCCC and patients with hypersensitivity
syndrome (HSS)

Figure 2. Population stratification detection using GWAS within the cohort of maculopapular exanthema
(MPE) cases from the EPIGEN consortium and healthy controls from the 1958 cohort. All participants
were self reported Europeans. Ethnicity was reported orally to clinician during investigations and
recorded in clinical notes.
Principal Components Analysis was performed to reduce subjects to a homogenous cluster of apparent
northern European ethnicity. The final cohort is shown below.

Figure 3. Results of MPE GWAS analysis

GWAS analysis involving MPE cases (n=43) and healthy controls from the 1958 British Birth Cohort
(n=1296). Significant EIGENSTRAT covariates are included as covariates in logistic regression model. The
top hit on chromosome six is HLA*3101 (P = 1.11 x 10-6).

Figure 4: Selection of imputed HLA-A*3101 samples following PCR amplification with sequence specific
primers.

Imputed positive sample lanes 1-4 contained a strong gel band as confirmation whereas the imputed
negative sample shown here in lane 5 contained no band.

